Sun Pharma
ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis
IL-23 inhibitor approved exclusively for healthcare provider-administered treatment Expands use of ILUMYA beyond moderate-to-severe plaque psoriasis…